RecruitingNCT06787105

Fruquintinib in Patients With Metastatic Colorectal Cancer

Fruquintinib in Patients With Metastatic Colorectal Cancer: A Prospective, Multicenter, Observational Study

Sponsor

iOMEDICO AG

Enrollment

150 participants

Start Date

Feb 17, 2025

Study Type

OBSERVATIONAL

Conditions

Metastatic Colorectal Cancer (Mcrc)

Summary

FRUQUENT is an observational study in Germany. The goal of the study is to evaluate how well Fruquintinib works to treat patients with metastatic colorectal cancer that have previously been treated with available standard therapies. To this end, it will be analyzed how well patients respond to the therapy in the clinical routine. Further points of interest to the study are survival data, safety data, the use of medical care facilities, and the quality of life of patients treated with Fruquintinib. Participants will be treated as decided by the treating physician and according to their routine practice. FRUQUENT is accompanied by a translational research project combining real-world clinical data with foundational research to stratify patient collectives in regards to the therapeutic benefit of fruquintinib.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This real-world study is tracking how well fruquintinib works and how safe it is in patients in Germany with metastatic colorectal cancer (bowel cancer that has spread) who have already tried multiple standard treatments. It follows patients receiving this drug as part of their regular clinical care. **You may be eligible if...** - You are 18 or older - You have metastatic colorectal cancer - You have already been treated with standard chemotherapy regimens (fluoropyrimidine, oxaliplatin, irinotecan), anti-VEGF therapy, and anti-EGFR therapy (if applicable) - Your cancer progressed on or you could not tolerate trifluridine/tipiracil or regorafenib - Your doctor has prescribed fruquintinib as per the approved German guidelines - You have signed informed consent **You may NOT be eligible if...** - You have not received the required prior treatments - Fruquintinib is not indicated for your specific situation per the drug label Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Onkologische Schwerpunktpraxis

Hanover, Lower Saxony, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06787105

Related Trials

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

NCT052868141 location

Evaluation of a Diagnostic Test to Identify the Best Drugs for Treatment of Metastatic Colorectal Cancer

NCT071715541 location

The Phase-2 CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen Trial (CLOVER)

NCT066998367 locations

Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

NCT0738926541 locations

DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit

NCT066452361 location